Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: Analysis of aetiology risk factors and outcome

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 3, 1998, Pages 373-380

  Krcmery, V ^a   Oravcova, E ^b   Spanik, S ^c   Mrazova Studena, M ^d   Trupl, J ^a   Kunova, A ^e   Stopkova Grey, K ^b   Kukuckova, E ^c   Krupova, I ^d   Demitrovicova, A ^a   Kralovicova, K ^e  

^a TRNAVA UNIVERSITY   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

^d St Elisabeth Cancer Institute Bratislava   (Slovakia)

^e Heydukova 10   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CLINICAL ARTICLE; CRYPTOCOCCUS; FEMALE; FUNGEMIA; HANSENULA; HOSPITAL INFECTION; HUMAN; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SLOVAKIA; TORULOPSIS GLABRATA; TRICHOSPORON BEIGELII;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INCIDENCE; ITRACONAZOLE; KETOCONAZOLE; MALE; MITOSPORIC FUNGI; NEOPLASMS; PICHIA; RETROSPECTIVE STUDIES; RISK FACTORS; SLOVAKIA; TREATMENT OUTCOME;

EID: 0031948743     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.3.373     Document Type: Article

References (21)

1. Wenzel, K. (1994). Epidemiology of nosocomial Candida infections. Current Opinion in Infectious Diseases 2,56.
2. Guiot, H. F. L, Fibbe, W. E. & van't Wout, J. W. I. (1994). Risk factors for fungal infections in patients with malignant hematologic disorders. Clinical Infectious Diseases 18, 535-41.
3. Wingard, J. R. (1994). Infections due to resistant Candida spp. in patients with cancer who are receiving chemotherapy. Clinical Infectious Diseases 19, Suppl. 1,49-53.
4. Dupont, B. (1994). Invasive fungal infections caused by yeasts as emerging pathogens. Current Opinion in Infectious Diseases 3, 78-83.
5. Stamos, J. K. & Rowley, A. H. (1995). Candidemia in a pediatric population. Clinical Infectious Diseases 20, 571-5.
6. Verweij, P. E., Donelly, J. P., Kuliberg, B. J., Weis, J. F. G. M. & De Pauw, B. E. (1994). Amphotericin B versus Amphotericin B plus 5-fluorocytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22, 81-5.
7. Meyers, J. D. (1990). Fungal infections in bone marrow transplant patients. Seminars in Oncology 17, Suppl. 3,10-13.
8. Goodman, J. L, Winston, D. J., Greenfield, R. A., Chandrawekar, P. H., Fox, B., Kaizer, H. er al. (1992). A controlled trial on fluconazole to prevent fungal infections in patients undergoing bone marrow transplantations. New England Journal of Medicine 326, 845-51.
9. Winston, D. J., Islam, Y., Buell, N. & Acute Leukemia Study Group. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 99, p. 43. American Society for Microbiology, Washington, DC.
10. Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, T. E. & Saral R. (1991). Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 325, 1274-7.
11. Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. G., Karp, J. E. & Saral, R. (1993). Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrobial Agents and Chemotherapy 37, 1847-9.
12. Rex, J. H., Pfaller, M. A., Barry, A. L, Nelson, P. W. & Webb, C. D. I. (1995). Antifungal susceptibility testing of isolates from randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidaemia. NIAID Mycoses Study Group and the Candidaemia Study Group. Antimicrobial Agents and Chemotherapy 39,40-4.
13. Kunova, A., Trupl, J., Spanik, S., Drgona, L, Sufliarsky, J., Lacka, J. et al. (1995). Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole. Chemotherapy 41, 39-44.
14. Iwen, P. C., Kelly, D. M., Reed, E. C. & Hinrichs, S. H. (1995). Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clinical Infectious Diseases 20,342-7.
15. Kunova, A., Trupl, J. & Krcmery, V. (1995). Breakthrough fungaemia due to Hansenula anomalo in a leukemic patient successfully treated with amphotericin B. Chemotherapy 42,157-8.
16. Kunova, A., Trupl, J., Spanik, S. & Krcmery, V. (1995) Breakthrough Trichosporon pullulans fungaemia despite prophylactic use of fluconazole. European Journal of Clinical Microbiology and Infectious Diseases 14,424-5.
17. Bonotte, B., Caillot, Solary, E., Lopey, J., Bailly, C., Casnovas, O. et al. (1995). Breakthrough candidemias in patients with haematologic malignancies. In Programme of New Trends in Fungal Infections, Manchester, 1995. Abstract 54, p. 54. Imedex, The Netherlands.
18. Rex, J. H., Rinaldi, M. G. & Pfaller, M. A. (1995). Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 39, 1-8.
19. Jakab, K., Kelemen, E., Prinz, G. & Torok, I. (1990). Amphotericin-resistant invasive hepatosplenic candidiasis controlled by fluconazole. Lancet 335,473-4.
20. Broughton, M. C., Bard, M. & Lees, N. D. (1991). Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34, 75-83.
21. Krcmery, V., Spanik, S., Kunova, A. & Trupl, J. (1997). Breakthrough fungaemia appearing during empiric therapy with amphotericin B. Chemotherapy 43, 113-6.